Ark is an end-to-end solution provider focused on early cancer detection. They harness advanced data science and their proprietary microRNA detection technology to develop accurate and cost-effective blood tests that can detect cancer at an early stage, when patients have the best chances of survival with timely treatment. Ark has its headquarters in Singapore, with R&D, manufacturing, and clinical diagnostic laboratory operations in China and USA. BEAMY was appointed as their brand consulting and design agency to build a complete brand system, including brand positioning, brand story, brand identity design, Chinese brand and product naming.
Focusing on the original intention of ARK and the positioning of the brand, BEAMY has named the Chinese brand for ARK - Pu (pǔ) Wei (wèi), Pu: Universal; wide-ranging; extensive; Wei: never before, early stage; future. Giving an association of wide-ranging, early, futuristic and high-tech, ARK helps many to defeat cancer at an early stage, provides reassurance of the unknown future. The infinite symbol / DNA chain extraction shape is incorporated into the logotype to portray that Ark, a life-related technology brand will expand the future infinite possibilities (cancer is no longer the end of life); the penetration rate of early screening will be infinitely close to the maximum. A sense of technology and futuristic neon green enhances the brand's validated technology and vision of the future. Green is also the color of leaves in nature. It has natural health and a sense of vision, which represents the infinite vitality vision that ARK has for the human life.
BEAMY's unique and precise brand positioning for ARK creates a unique brand that recognizes ARK's pioneering position in genetic biotechnology and expresses the infinite possibilities of ARK's technology to expand the future (cancer is no longer the end of life); the popularity of early screening is infinitely close to the maximum, giving the human life a stronger brand vision. Upon its launch, ARK received the attention of the mainstream media, and was listed “New Weekly” (one of China's most representative and public opinion magazines)’s annual new list as a “Life science breakthrough brand”. “ARK is a practitioner of the global cancer early screening technology. It is also an important force to change the world and rewrite the future with life science and technology. It makes talking about cancer history and long-term health becomes possible.” At the same time, Ark received a $40 million Series A round of financing from the health industry, and even domestic cross-industry companies and government support. It has successfully established 55 blood collection points in Beijing, Tianjin and Hangzhou.